This NORML article, published last month, sums up the FDA’s decision after several years of meetings, forums, information gathering, and due-diligence. Despite years of prodding by interested parties, as well as the general public, the FDA has finally concluded that instead of taking the lead on the issue, they will be working with Congress to develop a cross-agency strategy for the regulation of CBD products. They also denied several petitions to allow the marketing of CBD products as dietary supplements. Sadly, it seems we are in for more bureaucratic delays and red tape.
For more information, read the full NORML article here: https://norml.org/news/2023/02/02/fda-punts-on-establishing-rules-for-regulating-hemp-derived-cbd-products
To read the FDA’s press release, click here: https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol